New study tracks immune effects of NMOSD drug over years
NCT ID NCT06180278
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of inebilizumab (UPLIZNA) in people with neuromyelitis optica spectrum disorder (NMOSD). Researchers will measure immune markers like immunoglobulins and B-cells in 32 participants during treatment and after stopping. The goal is to understand how the drug affects the immune system over time and how it recovers after discontinuation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inebilizumab (UPLIZNA)
What this could lead to
If successful, this study could confirm that long-term use of inebilizumab is safe and help doctors understand when to stop or continue treatment for NMOSD.
What could go wrong
This is a small, open-label study with only 32 participants, so results may not apply to everyone. It focuses on safety, not on whether the drug works better than other options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-4202, United States
-
Khon Kaen University, Srinagarind Hospital - Division of Neurology, Depart
Khon Kaen, 40002, Thailand
-
M.A.-Lek A.M. Maciejowscy S.C. Centrum Terapii SM
Katowice, Silesian Voivodeship, 40-751, Poland
-
National Cancer Center - Neurology Clinic
Goyang-si, Gyeonggido [Kyonggi-do], 10408, South Korea
-
Prince of Wales Hospital (PWH) - The Chinese University of Hong Kong (CUHK) - Ophtalmology
Hong Kong, 0000, China
-
Samsung Medical Center - Pediatric Neurology
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, 6351, South Korea
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, 03080, South Korea
-
Szegedi Tudományegyetem, à OK, Szent-Györgyi Albert Klinikai Központ - Neurológiai Osztály
Szeged, Csongrád megye, 6725, Hungary
-
Uniwersyteckie Centrum Kliniczne WUM - Oddzial Kliniczny Neurologii
Warsaw, Masovian Voivodeship, 02-057, Poland
-
Vseobecna fakultni nemocnice v Praze - Neurologicka klinika
Prague, 128 21, Czechia
-
Wayne State University School of Medicine
Detroit, Michigan, 48201-2153, United States